Comparative Pharmacology
Head-to-head clinical analysis: AEMCOLO versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEMCOLO versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
AEMCOLO vs TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEMCOLO (crizotinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and mesenchymal-epithelial transition factor (MET). It inhibits ALK and ROS1 phosphorylation, blocking downstream signaling pathways involved in cell proliferation and survival.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby inhibiting thymidine synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides in Gram-negative bacteria.
AEMCOLO (rifamycin) delayed-release tablets: 600 mg orally twice daily for 3 days. Take with or without food.
One drop in each affected eye every 2 to 4 hours for 7 to 10 days.
None Documented
None Documented
Terminal elimination half-life is approximately 18-22 hours, supporting once-daily dosing for maintained intraluminal concentrations.
Trimethoprim: 8-10 hours (normal renal function); Polymyxin B: 6 hours (prolonged in renal impairment).
Primarily fecal elimination as unchanged drug; approximately 90% of a dose is recovered in feces, with less than 1% excreted unchanged in urine. Biliary excretion accounts for the remainder.
Trimethoprim: renal (80-90% unchanged, 10-20% metabolites); Polymyxin B: renal (60% unchanged, 40% nonrenal).
Category C
Category D/X
Antibiotic
Antibiotic